Paper Details

  1. Home
  2. Paper Details

Clinical and immune responses of tuberculosis patients treated with low-dose IL-2 and multidrug therapy.

Author: CorralL, JohnsonB J, LaochumroonvorapongP, LorgatF, LukeyP, PatiB P, RessS R, SahaR, SteadP, WillcoxP

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.
Research Support, U.S. Gov't, P.H.S.Research funding provided by the Public Health Service (PHS).

Overview

This study evaluated the safety and efficacy of recombinant human interleukin-2 (rhuIL-2) as an adjunct to multidrug therapy (MDT) for pulmonary tuberculosis (TB) in 20 patients. IL-2 administration in combination with conventional MDT was safe and may potentiate the antimicrobial cellular immune response to TB.
Paper Details　
Original Abstract of the Article :
The immune response to infection with M. tuberculosis depends on cytokine activation of effector cells. We therefore conducted a pilot study of recombinant human interleukin-2 (rhuIL-2) as an adjunct to multidrug therapy (MDT) to evaluate the safety of this approach and to determine whether IL-2 can...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://pubmed.ncbi.nlm.nih.gov/9384675

データ提供：米国国立医学図書館（NLM）

Boosting the Immune Response: IL-2 and Multidrug Therapy for Tuberculosis

Tuberculosis (TB), a contagious bacterial infection, continues to be a global health concern. This study investigates the potential benefits of adding low-dose interleukin-2 (IL-2) to multidrug therapy (MDT) for treating TB.

The Power of IL-2: A New Ally in the Fight Against TB

The study found that IL-2 therapy combined with MDT was safe and potentially enhanced the cellular immune response to TB. Patients receiving IL-2 experienced improvement in clinical symptoms, conversion to sputum-negative, and increased levels of interferon-gamma (IFN-gamma). These findings suggest that IL-2 may play a role in bolstering the immune system's ability to fight TB.

A Stronger Defense: IL-2's Impact on Immune Function

This study offers valuable insights into the potential benefits of IL-2 therapy as an adjunct to conventional MDT for treating TB. While further research is needed to fully understand the optimal dosage and long-term effects of IL-2, the results suggest that IL-2 may help strengthen the immune system's fight against TB.

Dr.Camel's Conclusion

Tuberculosis, a formidable adversary, is a reminder that even in the vast and unforgiving desert of disease, there is always hope for a cure. This research, like a beacon in the darkness, sheds light on the potential of IL-2 as a powerful weapon in the fight against TB. Remember, knowledge is our most valuable tool in conquering the challenges of disease.

Date :
  1. Date Completed 1997-12-08
  2. Date Revised 2013-05-27
Further Info :

Pubmed ID

9384675

DOI: Digital Object Identifier

9384675

Related Literature

Article Analysis
・Side Effects of aldesleukin
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.